Here are five recent GI/endoscopy company news updates.
AbbVie's hepatitis C drug cured 97 percent of patients who received a liver transplant in a recent trial, according to a Bloomberg report.
Boston Scientific Director Edward J. Ludwig bought 10,000 shares of the company's stock at an average cost of $13.38 per share for a total transaction of $133,800, according to a WKRB News & Analysis report.
EndoChoice received FDA 510(k) clearance for its Bonastent Tracheal/Bronchial device in October.
Frost & Sullivan awarded Metabolomic Technologies its 2014 North American Frost & Sullivan Award for Technology Innovation Leadership in recognition of the company's metabolomic screening test PolypDx.
The FDA approved SQI Diagnostics' proprietary Celiac Panel in the United States.
If you have a question, issue or note to suggest on a GI/endoscopy company please contact Carrie Pallardy at cpallardy@beckershealthcare.com.